bb2121: a promising outlook for the future of multiple myeloma

VJHemOnc has 1608 videos Subscribe Here

Description: The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the preliminary results of the trial and speaks about the possible advances that could be made as a result.
Shared By : VJHemOnc
Posted on : 08/10/18
Added : 11 months ago
Category : Multiple Myeloma